HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

American association for cancer research - 101st annual meeting - investigating new therapeutic candidates: part 1.

Abstract
The 101st Annual Meeting of the American Association for Cancer Research, held in Washington DC, included topics covering new therapeutic developments in the field of cancer research. This conference report highlights selected presentations on the development of the third-generation camptothecin analog TH-1320 (Threshold Pharmaceuticals Inc), the silencing of the androgen receptor in prostate cancer by the novel locked nucleic acid-based antisense oligonucleotide EZN-4176 (Enzon Pharmaceuticals Inc/Santaris Pharma A/S), the inhibition of PC-3 cell invasiveness and metastasis by the CXCR4 antagonist CTCE-9908 (British Canadian BioSciences Corp), the antitumor efficacy of the CDH3 mAb PPMX-2017 (Perseus Proteomics Inc), and an anti-IL-6 mAb (MedImmune LLC) that suppresses tumor growth in vivo.
AuthorsVicki L Mason
JournalIDrugs : the investigational drugs journal (IDrugs) Vol. 13 Issue 6 Pg. 357-9 (Jun 2010) ISSN: 2040-3410 [Electronic] England
PMID20506052 (Publication Type: Congress)
Chemical References
  • Antineoplastic Agents
Topics
  • Animals
  • Antineoplastic Agents (therapeutic use)
  • Cell Line, Tumor
  • Disease Models, Animal
  • Humans
  • Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: